GlaxoSmithKline Pharmaceuticals (GSK Pharma) is planning to start operations at its greenfield manufacturing facility at Bengaluru by 2017. Initially, the site will supply a range of solid dose form products. The unit will have an installed annual capacity of over 9 billion tablets and capsules to supply in the local market.
The new site, which represents up to Rs 1,000 crore in investments, will be the first greenfield pharma site GSK has built across the globe over the past 10 years. The state-of-the-art site will be the first factory designed for the new GSK production systems. The new unit is part of the strategic plan to rationalize.
GSK Pharma is one oldest pharmaceutical company in India. Internationally it has created many brands such as Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums and Zovirax, among others. It employs 5,000 people and has turnover of more than $1 billion in India.
